Apolipoprotein E isotype-specific effects in neurodegeneration

Alzheimer's Reports

Volumn 3, Issue 4, 2000, Pages 199-212

  Teter, Bruce ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 23044522049     PISSN: 14616130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (187)

1. Ahmed ARM, MacGowan SH, Culpan D et al. (1999). The-491 A/T polymorphism of the apolipoprotein E gene associated with the apoE epsilon 4 allele and Alzheimer's disease. Neurosci Lett. 263, 217-219.
2. Alvarez XA, Muozo R, Pichel V et al. (1999). Double-blind placebocontrolled study with citicoline in APOE genotyped Alzheimer's disease patients. Effects on cognitive performance brain bioelectrical activity and cerebral perfusion. Meth Find Exp Clin Pharmacol 21, 633-644.
3. Anderson R, Barnes JC, Bliss TVP et al. (1998). Behavioural, physiological and morphological analysis of a line of Apolipoprotein E knockout mouse. Neuroscience 85, 93-110
4. Aral H, Kashiwagi S, Nagasaka Y et al. (1999). Oxidative modification of apolipoprotein E (apoE) in human very-low-density lipoprotein and its inhibition by glycosaminoglycans. Arch Biochem Biophiys 367, 1-8.
5. Arendt T, Schindler C, Bruckner MK et al. (1997). Plastic neuronal remodeling is impaired in patients with Alzheimer's disease carrying apolipoprotein epsilon 4 allele. J Neurosci 17, 516-529.
6. Arendt T, Bruckner MK, Gertz HJ and Marcova L (1998). Cortical distribution of neurofibrillary tangles in Alzheimer's disease matches the pattern of neurons that retain their capacity of plastic remodeling in the adult brain. Neuroscience 83, 991-1002.
7. Artiga MJ, Bullido MJ, Frank A et al. (1998a). Risk for Alzheimer's disease correlates with transcriptional activity of the APOE gene. Hum Mol Genet 12, 1887-1892.
8. Artiga MJ, Bullido MJ, Sastre I et al. (1998b). Allelic polymorphisms in the transcriptional regulatory region of apolipoprotein E gene. FEBS 421, 105-108.
9. Bales KR, Verina T, Ghetti B et al. (1997). Lack of apolipoprotein E dramatically reduces amyloid ; -peptide deposition. Nature Genet 17, 263-264.
10. Bales KR, Verina T, Cummins DJ et al. (1999). Apolipoprotein E is essential for amyloid deposition in the APPv717f transgenic mouse model of Alzheimer's disease. PNAS 96, 15233-15238.
11. Barger SW and Harmon AD (1997). Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E. Nature 388, 878-881.
12. Barger SW and Mattson MP (1997). Isoform-specific modulation by apolipoprotein E of the activities of secreted beta-amyloid precursor protein. J Neurochem 69, 60-67.
13. Beffert U and Poirier J (1996). Apolipoprotein E plaques tangles and cholinergic dysfunction in Alzheimer's disease. Ann NY Acad Sci 777, 166-174.
14. Beffert U, Aumont N, Dea D et al. (1998a). Beta-amyloid peptides increase the binding and internalization of apolipoprotein E to hippocampal neurons. J Neurochem 70, 1458-1466.
15. Beffert U, Danik M, Krzywkowski P et al. (1998b). The neurobiology of apolipoproteins and their receptors in the CMS and Alzheimer's disease. Brain Res Rev 27, 119-142.
16. Beffert U, Aumont N, Dea D et al. (1999). Apolipoprotein E isoformspecific reduction of extracellular amyloid in neuronal cultures. Brain Res Mol Brain Res 68, 181-185.
17. Bellosta S, Nathan BP, Orth M et al. (1995). Stable expression and secretion of apolipoproteins E3 and E4 in mouse neuroblastoma cells produces differential effects on neunte outgrowth. J Biol Chem 270, 27063-27071.
18. Bennett C, Crawford F, Osborne A ef aJ. (1995). Evidence that the APOE locus influences rate of disease progression in late onset familial Alzheimer's Disease but is not causative. AmJMed Genet 60, 1-6.
19. Bertrand P, Poirier J, Oda Tet al. (1995). Association of apolipoprotein E genotype with brain levels of apolipoprotein E and apolipoprotein J (clusterin) in Alzheimer disease. Mol Brain Res 33, 174-178.
20. Blacker D, Haines JL, Rodes L et al. (1997). ApoE-4 and age at onset of Alzheimer's disease: the NIMH genetics initiative. Weurology 48, 139-147.
21. Boerwinkle E and Utermann G (1988). Simultaneous effects of the apolipoprotein E polymorphism on apolipoprotein E, apolipoprotein B and cholesterol metabolism. Am J Human Genet 42, 104-112.
22. Bondi MW, Salmon DP, Galasko D et al. (1999). Neuropsychological function and apolipoprotein E genotype in the preclinical detection of Alzheimer's disease. Psychol Aging 14, 295-303.
23. Breitner JCS, Wyse BW, Anthony JC ef al. (1999). APOE-epsilon 4 count predicts age when prevalence of AD increases then declines-The Cache County Study. Neurology 53, 321-323.
24. Bretsky PM, Buckwalter JG, Seeman TE et al. (1999). Evidence for an interaction between Apolipoprotein E genotype, gender and Alzheimer Disease. Alz Dis Assoc Disord 13, 216-221.
25. Bullido MJ, Artiga MJ, Recuero M et al. (1998). A polymorphism in the regulatory region of APOE associated with risk for Alzheimer's dementia. Nature Genet 18, 69-71.
26. Buttini M, Akeefe H, Lin C et al. (2000). Dominant negative effects of apolipoprotein (apo). E4 revealed in ApoE knockout mice coexpressing apoE3 and apoE4 in the brain. Neuroscience 97, 207-210.
27. Buttini M, Orth M, Bellosta S et al. (1999). Expression of human apolipoprotein ε 3 or ε 4 in the brains of apoe-/- mice: isoformspecific effects on neurodegeneration. J Neurosci 19, 4867-4880.
28. Carey-Bloom J, Tiraboschi P, Hansen LA (2000). E4 allele dosage does not predict cholinergic activity or synapse loss in Alzheimer's disease. Neurology 54, 403-406.
29. Caselli RJ, Graff-Radford NR, Reiman EM et al. (1999). Preclinical memory decline in cognitively normal apolipoprotein E-epsiIon4 homozygotes. Neurology 53 201-207.
30. Christen Y (2000). Oxidative stress and Alzheimer disease. Am J Clin Nutr-71, 621S-629S.
31. Corder EH, Saunders AM, Strittmatter WJ etal. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923.
32. Corder EH, Saunders AM, Risch NJ et al. (1994). Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nature Genet 7, 180-183.
33. Craft S, Teri L, Edland SD et al. (1998). Accelerated decline in apolipoprotein E-ε 4 homozygotes with Alzheimer's disease. Am Acad Neurol 51, 149-153.
34. Cullen P, Cignarella A, Brennhausen B etal. (1998). Phenotype-dependent differences in apolipoprotein E metabolism and in cholesterol homeostasis in human monocyte-derived macrophages. J Clin Invest 101, 1670-1677.
35. Cummings JL, Vinters HV, Cole GM and Khachaturian ZS (1998). Alzheimer's Diease: Etiologies pathophysiology cognitive reserve and treatment opportunities. Neurology 51 (suppl 1)S2-S17.
36. Danik M and Poirier J (1998). Apolipoprotein E and neuronal plasticity following experimental de-afferentation and in Alzheimer's disease. Biochem Soc Trans 26, 262-266.
37. De Knijff P and van Duijn CM (1998). Role of APOE in Dementia: A Critical Reappraisal. Haemostasis 28, 195-201.
38. DeMattos RB, Thomgate FE and Williams DL (1999). A test of cytosolic apolipoprotein E hypothesis fails to detect the escape of apolipoprotein E from the endocytic pathway into the cytosol and shows that direct expression of apolipoprotein E in the cytosol is cytotoxic. J Neurosci 19, 2464-2473.
39. DeMattos RD, Curtiss LK and Williams DL (1998). A minimally lipidated form of cell-derived apolipoprotein E exhibits isoform-specific stimulation of neurite outgrowth in the absence of exogenous lipids or lipoproteins. J Biol Chem 273, 4206-4212.
40. Dong LM, Wilson C, Wardell MR et al. (1994). Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem 269, 22358-22365.
41. Dong LM, Innerarity T, Arnold K et al. (1998). The carboxyl terminus in apolipoprotein E2 and the seven amino acid repeat in apolipoprotein E-leiden: role in receptor-binding activity. J Lipid. Res 39, 1173-1180.
42. Evans KG, Berger EP, Cho CG et al. (1995). Apolipoprotein E is a kinetic but not a thermodynamic inhibitor of amyloid formation: Implicatioins for the pathogenesis and treatment of alzheimer disease. Proc Natl Acad Sci USA 92, 763-767.
43. Pagan AM, Bu G, Sun Y et al. (1996). Apolipoprotein E-containing high density lipoprotein promotes neurite outgrowth and is a ligand for the low density lipoprotein receptor-related protein. J Biol Chem 271, 30121-30125.
44. Farlow MR, Lahiri DK, Poirier J et al. (1998). Treatment outcome of tacrine therapy depends on apolipoprotein genotype and gender of the subjects with Alzheimer's disease. Neurology 50, 669-677.
45. Farrer LA, Cupples LA, van Duijn CM et al. (1995). Apolipoprotein E genotype in patients with Alzheimer's disease: implications for the risk of dementia among relatives. Ann Neurol 38, 797-808.
46. Farrer LA, Cupples LA, Haines JL et at. (1997a). Effects of age sex and ethnicity on the association between apoliporotein E genotype and Alzheimer disease. Meta-analysis of APOE and Alzheimer Disease. JAMA 278, 1349-1356.
47. Farrer LA, Cupples LA, Kukull WA et al. (1997b). Risk of Alzheimer disease is associated with parental age among apolipoprotein E heterozygotes. Alz Res 3, 83-91.
48. Frisoni GB, Manfredi M, Geroldi C etal. (1998). The prevalence of apoE-epsilon4 in Alzheimer's disease is age dependent. J Neurol Neurosurg Psychiatr 65, 103-106.
49. Gearing M, Mori H and Mirra SS (1996). Ap-peptide length and apolipoprotein E genotype in Alzheimer's disease. Ann Neurol 39, 395-399.
50. Ghebremedhin E, Schultz C, Braak E and Braak H (1998). High frequency of apolipoprotein E e4 allele in young individuals with very mild Alzheimer's disease-related neurofibrillary changes Exp Neurol 153, 152-155.
51. Gregg RE, Zech LA, Schaefer EJ et al. (1986). Abnormal in vivo metabolism of apolipoprotein E4 in humans. J Clin Invest 78, 815-821.
52. Growdon JH (1998). Apolipoprotein E and Alzheimer Disease. Arch Neurol 55, 1053-1054.
53. Growdon JH, Cheung BS, Hyman BT and Rebeck GW (1999). Lack of allelic imbalance in APOE s3le4 brain mRNA expression in Alzheimer's disease. Neurosci Lett 272, 83-86.
54. Guillaume D, Bertand P, Dea D et al. (1996). Apolipoprotein E and low-density lipoprotein binding and internalization in primary cultures of rat astrocytes: isoform-specific alterations. J Neurochem 66, 2410-2418.
55. Guo Z, Cupples LA, Kurz A and Auerbach SH (2000). Head Injury and the risk of AD in the MIRAGE study. Neurology 54, 1316-1323.
56. Gutman CR, Strittmatter WJ, Weisgraber KH and Matthew WD (1997). Apolipoprotein E binds to and potentiates to biological activity of ciliary neurotrophic factor. J Neurosci 17, 6114-6121.
57. Haan MN, Shemanski L, Jagust WJ, Manolio TA and Kuller L (1999). The role of APOE epsilon4 in modulating effects of other risk factors for cognitive decline in elderly persons JAMA 282, 40-46.
58. Handelmann GE, Boyles JK, Weisgraber KH (1992). Effects of apolipoprotein E, ; -very low density lipoproteins and cholesterol on the extension of neuntes by rabbit dorsal root ganglion neurons In vitro. J Lipid Res 33, 1677-1688.
59. Harr SD, Vint L, Hollister R et al. (1996). Brain expression 'of Apolipoprotein E, J and A-l in Alzheimer's disease. J Neurochem 66, 2429-2435.
60. Higgins GA, Large CH, Rupniak HT and Barnes JC (1997). Apolipoprotein E and Alzheimer's disease: A review of recent studies. Pharmacol Biochem Behav 56, 675-685.
61. Hirono N. Mori E, Yasuda M et al. (1998). Lack of association of apolipoprotein E epsilon4 allele dose with cerebral glucose metabolism in Alzheimer disease. Alz Dis Assoc Disord 12, 362-367.
62. Holtzman DM, Pitas RE, Kilbridge J et al. (1995). Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. Proc NatlAcad Sei USA 92, 9480-9484.
63. Holtzman DM and Pagan AM (1998). Potential role of apoE in structural plasticity in the nervous system- implications for disorders of the central nervous system. TrendCardiovascMedS, 250-255.
64. Holtzman DM, Bales RK, Wu S et al. (1999). Expression of human apolipoprotein E reduces amyloid-B deposition in a mouse model of Alzheimer's disease. J Clin Invest 103, R15-R21.
65. Holtzman DM, Bales KR, Tenkova T et al. (2000a). Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneraton in a mouse model of Alzheimer's disease. Proc Natl Acad Sei USA 97, 2892-2897.
66. Holtzman DM, Pagan AM, Mackey B et al. (2000b). Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol 47, 739-747.
67. Horsburgh K, McCulloch J, Nilsen M et al. (2000). Intaventricular infusion of apolipoprotein E ameliorates acute neuronal damage after global cerebral ischemia in mice. J Cerebr Blood Flow Metab 20, 458-462.
68. Huang DY, Goedert M, Jakes R et al. (1994). Isoform-specific interactions of apolipoprotein E with the microtubule-associated protein MAPA2c: implications for Alzheimer's disease. Neurose; Lett 182, 55-58.
69. Huang DY, Weisgraber KH, Strittmatter WJ and Matthew WD (1995). Interaction of Apolipoprotein E with laminin increases neuronal adhesion and alters neurite morphology. Exp Neurol 136, 251-257.
70. Inestrosa NC, Marzolo MP and Bonnefont AB (1998). Cellular and molecular basis of estrogen's neuroprotection. Potential relevance for Alzheimer's disease. Mol Neurobiom, 73-86.
71. Jarvik GP, Wijsman EM, Kukull WA et al. (1995). Interactions of apolipoprotein E genotype, total cholesterol level age and sex in prediction of Alzheimer's disease: a case-control study. Neurology 45, 1092-1096.
72. Ji Z, Fazio S and Mahley RW (1994). Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. JBiolChem269, 13421-13428.
73. Ji ZS, Pitas RE and Mahley RW (1998). Differential cellular accumulation/retention of apolipoprotein E mediated by cell surface heparan sulfate proteoglycans. JBiol Chem 273, 13452-13460.
74. Johannsson G, Oscarsson J, Rosen T et al. (1995). Effects of growth hormone therapy on serum lipoprotein levels in growth hormone deficient adults. Influence of gender and apo(a) and apoE phenotypes. Arterio Thromb Vase Biol 15, 2142-2150.
75. Johnson JK, McCleary R, Oshita MH and Cotman CW (1998). Initiation and propagation stages of beta-amyloid are associated with distinctive apolipoprotein E age and gender profiles. Brain Res 798, 18-24.
76. Jolivalt C, Lenninger-Muller B, Bertrand P et al. (2000). Differential oxidation of apolipoprotein E isoforms and interaction with phospholipids. Free Rad Biol Med 28, 129-140.
77. Jordan J, GalindoMF, Miller RJ et al. (1998). Isoform-specific effect of apolipoprotein E on cell survival and ; -amyloid-induced toxicity in rat hippocampal pyramidal neuronal cultures. J Neurosci 18, 195-204.
78. Juottonen K, Lehtovirta M, Helisalmi S and Riekkinen PJ (1998). Major decrease in the volume of the entorhinal cortex in patients with Alzheimer's disease carrying the apolipoprotein E epsilon 4 allele. J Neurol Neurosurg Psychiatr 65, 322-327.
79. Juva K, Verkkoniemi A, Viramo P et al. (2000). APOE epsilon4 does not predict mortality cognitive decline or dementia in the oldest old. Neurology 54, 412-415.
80. Katzman R, Rang D and Thomas R (1998). Interaction of apolipoprotein E epsilon 4 with other genetic and non-genetic risk factors in late onset Alzheimer disease: problems facing the investigator. Neurochem Res 23, 369-376.
81. Kehoe P, Krawczak M, Harper PS and Owen MJ (1999). Age of onset in Hunington disease: sex specific influence of apolipoprotein E genotype and normal CAG repeat length. J Med Genet 36, 108111.
82. Kerr ME and Kraus M (1998). Genetics and the central nervous system: Apolipoprotein E and brain injury. AACN Clinical Issues 9, 524-530.
83. Kowal RC, Herz J, Weisgraber KH et al. (1990). Opposing effects of apolipoproteins E and C on lipoprotein binding to low density lipoprotein receptor-related protien. J Biol Chem 26510771-10779.
84. Kruger R, Vieira-Saecker AMM, Kuhn W ef al. (1999). Increased susceptibility to sporadic Parkinson's disease by a certain combined alpha-synuclein/apolipoprotein E genotype. Ann Ateuro/45, 611-617.
85. Kukull WA and Martin GM (1998). APOE polymorphisms and lateonset Alzheimer disease. JAMA 279, 788-789.
86. LaDu MJ, Falduto MT, Manelli AM et at. (1994). Isoform-specific binding of apolipoprotein E to ; -amyloid. J Biol Chem 269, 23403-23406.
87. Lambert JC, Perez-Tur J, Dupire MJ etal. (1997). Distortion of allelic expression of apolipoprotein E in Alzheimer's disease. Hum Mol Genet 6, 2151-2154.
88. Lambert JC, Berr C, Pasquier F et al. (1998). Pronounced impact of Th1/E47cs mutation compared with -491 AT mutation on neural APOE gene expression and risk of developing Alzheimer's disease. Hum Mol Genet 7, 1511-1516.
89. Laping NL, Nichols NR, Rozovsky IR et al. (1994). "Symposium on GFAP" Glial Fibrillary Acidic Protein: Regulation by Hormones Cytokines and Growth Factors. Brain PatholA, 259-275.
90. Larkin M (2000). APOE ε 4 foils oestrogen's effects on cognitive decline. Lancet 355, 1889.
91. Laskowitz DT, Horsburgh K and Roses AD (1998). Apolipoprotein E and the CNS response to injury. J Cerebr Blood Flow Metab 18, 465-471.
92. Laws SM, Taddei K, Martins G et al. (1999). The -491 AA polymorphism in the APOE gene is associated with increased plasma apoE levels in Alzheimer's disease. AteuroReporMO, 879-882.
93. Le Bars PL, Katz MM, Berman N et al. (1997). A placebo-controlled double-blind randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278, 1327-1332.
94. Lefranc D, Vermersch P, Dallongeville J et al. (1996). Relevance of the quantification of apolipoprotein E in the cerebrospinal fluid in Alzheimer's disease. Neurosci Lett 212, 91-94.
95. Lehtimaki T, Pirttila T, Mehta PM et al. (1995). Apolipoprotein E (apoE) polymorphism and its influence on ApoE concentrations in the cerebrospinal fluid in Finnish patients with Alzheimer's disease. Hum Genet 95, 39-42.
96. Lehtovirta M, Kuikka J, Helisalmi S et al. (1998). Longitudinal SPECT study in Alzheimer's disease: relation to apolipoprotein E polymorphism. J Neurol Neurosurg Psychiatr 64, 742-746.
97. Licastro F, Mallory M, Hansen LA and Masliah E (1998). Increased levels of alpha-1 -antichymotrypsin in brains of patients with Alzheimer's disease correlate with activated astrocytes and are affected by APOE 4 genotype. J Neuroimmunol SB, 105-110.
98. Lippa CF, Smith TW, Saunders AM et al. (1997). Apolipoprotein E-s2 and Alzheimer's disease: genotype influences pathologic phenotype. Neurology 48, 515-519.
99. Lomnitski L, Kohen R, Chen Y et al. (1997). Reduced levels of antioxidants in brains of apolipoprotein E-deficient mice following closed head injury. Pharmacol Biochem Behav 56, 669-673.
100. Lovestone S, Anderton BH, Hartley C et al. (1996). The intracellular fate of apolipoprotein E is tau dependent and apoe allele-specific. Neuro Report T, 1005-1008.
101. 1-antichymotrypsin and apolipoprotein E promote assembly of Alzheimer ; -protein into filaments. Nature 372, 92-94.
102. MacGowan SH, Wilcock GK and Scott M (1998). Effect of gender and apolipoprotein E genotype on response to anticholinesterase therapy in Alzheimer's disease. Intl J Geriatr Psychiatr 13, 625630.
103. Mahley R and Huang Y (1999). Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. Curr Opin Lipidol 10, 207-217.
104. Mahley RW (1988). Apolipoprotein E: Cholesterol transport protein with expanding role in cell biology. Science 240, 522-630.
105. Mahley RW (1996). Heparan sulfate proteoglycans/low density lipoprotein receptor-related protein pathway involved in type III hyperlipoproteinemia and Alzheimer's disease. Israel J Med Sci 32, 414-116.
106. Markesbery W and Carney JM (1999). Oxidative alterations in Alzheimer's disease. Brain Pathol 9, 133-146.
107. Marques MA, Harmony JA and Crutcher KA (1996). A thrombin cleavage fragment of apolipoprotein E and related synthetic peptides is receptor-mediated. Neuro Report T, 2529-2532.
108. Masliah E, Mallory M, Veinbergs l et al. (1996). Alterations in apolipoprotein E expression during aging and neurodegeneration. Progr Neurobiol 50, 493-503.
109. Masliah E, Samuel W, Veinbergs I eraJ. (1997). Neurodegeneration and cognitive impairment in apoE-deficient mice is ameliorated by infusion of recombinant apoE. Brain Res 751, 307-314.
110. Mattila KM, Axelman K, Rinne JO et al. (2000). Interaction between estrogen receptor 1 and the ε allele of apolipoprotein E increases the risk of familial Alzheimer's disease in women. NeurosciLett 282, 45-48.
111. Mayeux R, Ottman R, Maestre G et al. (1995). Synergistic effects of traumatic head injury and apolipoprotein-ε 4 in patients with Alzheimer's disease. Neurology 45, 555-557.
112. Mesulam MM (1999). Neuroplasticity failure in Alzheimer's disease: bridging the gap between plaques and tangles. Neuron 24, 521-529
113. Michaelis EK (1998). Molecular biology of glutamate receptors in the central nervous system and their role in excitotoxicity, oxidative stress and aging. Progr Neurobiol 54, 369-415
114. Michikawa M and Yanagisawa K (1998). Apolipoprotein E4 isoformspecific actions on neuronal cells in culture. Mech Ageing Dev 107, 233-243.
115. Michikawa M, Fan Q-W, Isobe I and Yanagisawa K (2000). Apolipoprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neurochem 74, 1008-1016.
116. Mielke R and Heiss WD (1998). Positron emission tomography for diagnosis of Alzheimer's disease and vascular dementia. J Neural Transm 53, 237-250.
117. Mielke R, Zerres K, Uhlhaas S and Kessler J (1998). Apolipoprotein E polymorphism influences the cerebral metabolic pattern in Alzheimer's disease. Neurosci Lett 254, 49-52.
118. Miyata M and Smith JD (1996). Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and B-amyloid peptides. Nature Genet 14, 55-61.
119. Moceri VM and Kukull WA (2000). Early-life risk factors and the development of Alzheimer's disease. Neurology 54, 415-420.
120. Montine K, Reich E, Neely MD eraJ. (1998). Distribution of reducible 4-Hydroxynonenal adduct immunoreactivity in Alzheimer's disease is associated with APOE genotype. J Neuropathol Exp Neurol 57, 415-425.
121. Montine T, Montine KS, Olson SJ et al. (1999). Increased cerebral cortical lipid peroxidation and abnormal phospholipids in aged homozygous apoE-deficient C57BL/6J mice. Exp Neurol 158 234-241.
122. Montine TJ, Huang DY, Valentine WM et al. (1996). Crosslinking of apolipoprotein E by products of lipid peroxidation. J Neuropathol Exp Neural 55, 202-210.
123. Montine TJ, Montine KS and Swift LL (1997). Central nervous system lipoproteins in Alzheimer's disease. Am J Palhol 151, 1571-1575.
124. Morris JC (1999). Is Alzheimer's disease inevitable with age? J Clin In vesM 04, 1171-1172.
125. Mui S, Briggs M, Chung H et al. (1996). A newly identified polymorphism in the apolipoprotein E enhancer gene region is associated with Alzheimer's disease and strongly with the e4 allele. Neurology 47, 196-201.
126. 2+-channel. Brain PatholS, 641-653.
127. Nagy Z, Estiri MM, Jobst KA et al. (1995). Relative roles of plaques and tangles in the dementia of Alzheimer's disease: correlations using three sets of neuropathological criteria. Dementia 6, 21-31.
128. Nathan BP, Bellosta S, Sanan DA eraJ. (1994). Differential effects of apolipoproteins E3 and E4 on neuronal growth in vitro. Science 264, 850-852.
129. Nathan BP, Chang K, Bellosta S et al. (1995). The inhibitory effect of apolipoprotein E4 on neurite outgrowth is associated with microubule depolymerization. JBiolChem 270, 19791-19799.
130. Nicoll JA, Roberts GW and Graham Dl (1996). Amyloid beta-protein APOE genotype and head injury. Ann NY Acad Sei 777, 271-275.
131. Ohm TG, Scharnagel H, Marz W and Bohl J (1999). Apolipoprotein E isoforms and the development of low and high Braak stages of Alzheimer's disease-related lesions. Acta Neuropathologica 98, 273-280.
132. Overmyer M, Helisalmi S, Soininen H eraJ. (1999). Astrogliosis and the ApoE genotype. An immunohistochemical study of postmortem human brain tissue. Dement Geriatr Cogn Disord 10, 252-257.
133. Oyama F, Shimada H, Oyama R and Ihara Y (1995). Apolipoprotein E genotype, Alzheimer's pathologies and related gene expression in the aged population. Mol Brain Res 29, 92-98.
134. Payami H, Kaye J, Heston LL et al. (1993). Apolipoprotein E genotype and Alzheimer's disease. Lancet 342, 738.
135. Pedersen WA, Chan SL and Mattson MP (2000). A mechanism for the neuroprotective effect of apolipoprotein E: Isoform-specific modification by the lipid peroxidation product 4-hydroxynonenal. J Neurochem74, 1426-1433.
136. Pirttila T, Lehtimaki T, Nikkari T et al. (1995). Apolipoprotein E c4 allele and risk of dementia JAMA 273, 375-376.
137. Pirttila T, Soininen H, Heinonen O et al. (1996). Apolipoprotein E (apoE) levels in brains from Alzheimer's disease patients and controls. Brain Res 722, 71-77.
138. Pirttila T, Soininen H, Mehta PD eraJ. (1997). Apolipoprotein E genotype and amyloid load in Alzheimer disease and control brains. Neurobiol Aging 18, 121-127.
139. Plassman BL, Welsh-Bohmer KA, Bigler ED et al. (1997). Apolipoprotein E e4 allele and hippocampal volume in twins with normal cognition. Neurology 48, 985-989.
140. Poirier J, Davignon J, Bouthillier D et al. (1993). Apolipoprotein E polymorphism and Alzheimer's disease. Lancer 342, 697-699.
141. Poirier J (1994). Apolipoprotein E in animal models of CNS injury and in Alzheimer's disease. Trends Neurosci 17, 525-530.
142. Poirier J, Delisle M-C, Quirion R et al. (1995). Apolipoprotein E4 allele as a predictor of cholinergic deficits and treatment outcome in Alzheimer disease. Proc Nail Acad Sei USA 92, 12260-12264.
143. Poirier J (1999). Apolipoprotein E: a pharmacogenetic target for the treatment of Alzheimer's disease. Mol Diagn 4, 335-341.
144. Pratico D, Clark CM, Lee VYM et al. (2000). Increased 8, 12-isoiPF2alpha VI in Alzheimer's disease: Correlation of non-invasive index of lipid peroxidation with disease severity. Annal Neurol in press.
145. Puttfarcken PS, Manelli AM, Falduto MT ef al. (1997). Effect of apolipoprotein E on neurite outgrowth and ; -amyloid-induced toxicily in developing rat primary hippocampal cultures. J Neureichem 68, 760-769.
146. Raber J, Wong D, Buttini M et al. (1998). Isoform-specific effects of human apolipoprotein E on brain function revealed in apoE knockout mice: increased susceptibility of females. Proc Natl Acad Sei USA 95, 10914-10919.
147. Raber J, Wong D, Yu G-Q et al. (2000). Apolipoprotein E and cognitive performance. Nature 404, 352-253.
148. Ramassamy C, Averill D, Beffert U et al. (1999). Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to apolipoprotein E genotype. Free Rad Biol Med 27, 544-553.
149. Ramassamy C, Averill D, Beffert U et al. (2000). Oxidative insults are associated with apolipoprotein E genotype in Alzheimer's disease brain. Neurobiol Dis 7, 23-37.
150. Ravaja N, Raikkonen K, Lyytinen H and Lehtimaki T (1997). Apolipoprotein E phenotypes and cardiovascular responses to experimentally induced mental stress in adolescent boys. J Behavior Med 20, 571-587.
151. Rebeck GW, Reiter JS, Strickland DK and Hyman BT (1993). Apolipoprotein E in sporadic Alzheimer's disease: allelic variation and receptor interactions. Neuron 11, 575-580.
152. Reed T, Carmelli D, Swan GE et al. (1994). Lower cognitive performance in normal older adult male twins carrying the apolipoprotein E epsilon 4 allele. Arch Neurol 51, 1189-1192.
153. Reiman EM, Caselli RJ, Yun LS et al. (1996). Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. New Engl JMed334, 752-758.
154. Richard F, Helbecque N, Neuman E et al. (1997). ApoE genotyping and response to drug treatment in Alzheimer's disease. Lancet 349, 539.
155. Ritchie K and Dupuy AM (1999). The current status of APOE ε 4 as a risk factor for Alzheimer's disease: an epidemilogical perspective. Intl J Geriatr Psychiatr14, 695-700.
156. Roks G, Cruts M, Bullido MJ et al. (1998). The -491 A/T polymorphism in the regulatory region of the apolipoprotein E gene and early-onset Alzheimer's disease. Neurosci Lett 258, 65-68.
157. Roses AD (1994). Apolipoprotein E affects the rate of Alzheimer disease expression: beta-amyloid burden is a secondary consequence dependent on APOE genotype and duration of disease. J Neuropathol Exp Neurol 53, 429-437.
158. Roses AD (1997). Apolipoprolein E, a gene with complex biological interactions in the aging brain. Neurobiol Dis 4, 170-186.
159. Roses AD and Saunders AM (1997). ApoE Alzheimer's disease and recovery from brain stress Ann NY Acad Sci 826, 200-212.
160. Roses AD, Gilbert J, Xu PT et al. (1998). Cis-acting human apoE tissue expression element is associated with human pattern of intraneuronal apoE in transgenic mice. Neurobiol Aging 19, S53-S58.
161. Russo C, Angelini G, Dapino D et al. (1998). Opposite roles of apolipoprotein E in normal brains and in Alzheimer's disease. Proc Natl Acad Sci USA 95, 15598-15602.
162. Saitoh T, Kang D, Mallory M et al. (1997). Glial cells in Alzheimer's disease: preferential effect of APOE risk on scattered microglia. Gerontology 43, 109-118.
163. Salamone LM, Cauley JA, Zmuda J et al. (2000). Apolipoprotein E gene polymorphism and bone loss: estrogen status modifies the influence of apolipoprotein E on bone loss. J Bone Min Res 15, 308-314.
164. Salehi A, Lucassen PJ, Pool CW et al. (1994). Decreased neuronal activity in the nucleus basalis of Meynert in Alzheimer's disease as suggested by the size of the golgi apparatus. Neuroscience 59, 871-880.
165. Sanan DA, Weisgraber KH, Russell S J et al. (1994). Apolipoprotein E associates with b amyloid peptide of Alzheimer's disease to form novel monofibrils. J Clin Invest 94, 860-869.
166. Sano M, Ernesto C, Thomas RG et al. (1997). A controlled trial of selegiline, alpha-tocopherol or both as treatment for Alzheimer's disease. The Alzheimer's Disease cooperative study. New Engl J Med 336, 1216-122.
167. Saunders AM, Strittmatter WJ, Schmechel D et al. (1993). Association of apolipoprotein E allele ε 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43, 1467-1472.
168. Saunders AM, Hulette O, Welsh-Bohmer KA et al. (1996). Specificity sensitivity and predictive value of apolipoprotein-E genotyping for sporadic Alzheimer's disease. Lancer 348, 90-93.
169. Schachter F, Faure-Delanef L, Guenot F et al. (1994). Genetic associations with human longevity at the APOE and ACE loci. Nature Genet 6, 29-32.
170. Schmechel DE, Saunders AM, Strittmatter et al. (1993). Increased amyloid ; -peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Pmc Natl Acad Sci USA 90, 9649-9653.
171. Schneider LS and FarlowM (1997). Combined tacrineand estrogen replacement therapy in patients with Alzheimer's disease. Ann NY Acad Sci 826, 317-322.
172. Sheng H, Laskowitz DT, Bennett E et al. (1998). Apolipoprotein E isoform-specific differences in outcome from focal ischemia in transgenic mice. J Cerebr Blood Flow Metab 18, 361-366.
173. Sisodia SS (1999). Alzheimer's disease: perspectives for the new millennium. J Clin Invest 104, 1169-1170.
174. Sjoberg A, Oscarsson J, Eden S and Olofsson SO (1994). Continuous but not intermittent administration of growth hormone to hypophysectomized rats increases apolipoprotein-E secretion from cultured hepatocytes. Endocrinology 134, 790-798.
175. Slooter AJ, Tang MX, van Duijn CM et al. (1997). Apolipoprotein E epsilon 4 and the risk of dementia with stroke. A population-based investigation. JAMA 277, 818-821.
176. Slooter AJC, Cruts M, Kalmijn S et al. (1998). Risk estimates of dementia by apolipoprotein E genotypes from a population-based incidence study: The Rotterdam Study. Arch Neurol 55, 964-968.
177. Small BJ, Basun H and Backman L (1998). Three-year changes in cognitive performance as a function of apolipoprotein E genotype: evidence from very old adults without dementia. Psychol Aging 13, 80-87.
178. Small GW, Mazziotta JC, Collins MT et al. (1995). Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer disease. JAMA 273, 942-947.
179. Small GW, Komo S, La Rue et al. (1996). Early detection of Alzheimer's disease by combining apolipoprotein E and neuroimaging. Ann NY Acad Sci 802, 70-80.
180. Smith GE, Bohac DL, Waring SC et at. (1998). Apolipoprotein E genotype influences cognitive 'phenotype' in patients with Alzheimer's disease but not in healthy control subjects. Neurology 50, 355-362.
181. Smith JD, Miyata M, Ginsberg M et al. (1996). Cyclic AMP induces apolipoprotein E binding activity and promotes cholesterol efflux from a macrophage cell line to apolipoprotein acceptors. J Biol Chem 271, 30647-30655.
182. Smith JD, Sikes J and Levin JA (1998). Human apolipoprotein E allele-specific brain expressing transgenic mice. Neurobiol Aging 19, 407-413.
183. Song YQ, Rogaeva E, Premkumar S et al. (1998). Absence of association between Alzheimer disease and the -491 regulatory region polymorphism of APOE. Neurosci Lett 250, 189-192.
184. Soulie C, Valerie M, Dupont-Wallois L et al. (1999). Synthesis of apolipoprotein E (ApoE) mRNA by human neuronal type SK N SH-SY 5Y cells and its regulation by nerve growth factor and ApoE. Neurosci Lett 265.
185. Staehelin HB, Perrig-Chiello P, Mitrache C ef aJ. (1999). Apolipoprotein E genotypes and cognitive functions in healthy elderly persons. Acta Neurol Scand 100, 53-60.
186. Stern Y, Brandt J, Albert M et al. (1997). The absence of an apolipoprotein ε 4 allele is associated with a more aggressive form of Alzheimer's disease. Ann Neurol 41, 615-620.
187. Stevens M, van Duijn CM, de Kniff P et al. (1997). Apolipoprotein E